Long Ideas - Hyperion Therapeutics (NASDAQ:HPTX) received two Buy ratings this morning after going public in late July. Both Cowen and Needham initiated coverage on HPTX, with Needham … Continue Reading
Read now- StemCells, Inc. (NASDAQ:STEM) is down 9% this morning after a downgrade from Roth Capital lowered STEM’s price target from $5.00 to $1.80; a “Buy” rating … Continue Reading
Read now- Investors will have to wait a few more weeks to find out whether Amarin’s (NASDAQ:AMRN) recently approved Vascepa high-triglyceride treatment will receive New Chemical Entity … Continue Reading
Read now- Developer of the recently-approved Qsymia weight-loss drug, Vivus, (NASDAQ:VVUS) is down 7% this morning after a downgrade from Jefferies; the analyst gave Vivus a new … Continue Reading
Read nowLong Ideas - Shares of Medtronic (NYSE:MDT) are expected to be strong today and through the company’s fiscal 1Q 2013 earnings report next week, with a big upgrade … Continue Reading
Read nowLong Ideas - After yesterday’s news from Idenix Pharmaceuticals (NASDAQ:IDIX) and the ensuing 30% sell-off, Gilead Sciences (NASDAQ:GILD) saw a small decline in share price. Gilead’s lead Hepatitis … Continue Reading
Read nowLong Ideas - Pfizer’s (NYSE:PFE) developmental drug tofacitinib, originally indicated for Rheumatoid Arthirits, showed positive trial results in treating ulcerative colitis and has been moved into a Phase … Continue Reading
Read now